ClinicalTrials.gg
RecruitingNCT06442579Updated Sep 21, 2026

The Influence of Cortical Lateralization on Selective Motor Control of the Arm Swing During Independent Walking After Stroke.

An interventional study of Walking on a treadmill in Healthy and Stroke, sponsored by University Hospital, Ghent. Recruiting at 2 sites in Belgium. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stroke by University Hospital, Ghent — 9 open to participants now, 9 under way, none of them phase 3. Stroke · University Hospital, Ghent.

Planned enrollment
5th of 13
84 · median 30
Started
2024
with 1 other
No phase
13 of 18
6 open now
Registered
13th of 18
by date

Among the 18 studies in Stroke by University Hospital, Ghent, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 13th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 18 studies in Stroke by University Hospital, Ghent are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by University Hospital, Ghent, or all of them as a file.
02

Study summary

The upper limbs play an essential role for safe and efficient walking in healthy persons and persons post-stroke. Nevertheless, in current post-stroke gait rehabilitation (research) the upper limbs are barely targeted. To address this gap, my project aims to investigate the selective motor control of the upper limbs during walking and the contribution of the cortical activity to the arm swing in independent walkers after stroke.

To gain insight in the direct effects of stroke on the arm swing, the primary motor control of the arm swing will be evaluated by determining muscle synergies (i.e group of muscles working together as a task-specific functional unit). Additionally, the cortical activity (EEG-analysis) during walking of persons post-stroke will be compared to healthy controls and the relationship between stroke-induced changes in cortical activity and arm swing deviations will be assessed. Furthermore, I will evaluate whether improvements in cortical activity relate to improvements in primary motor control of the arm swing.

This innovative project will be the first to investigate the direct coupling between the cortex and the muscle synergies in persons post-stroke during independent walking to investigate the arm swing. These fundamental insights in the primary motor control of the arm swing and the contribution of the cortical activity will allow to develop targeted interventions aiming to improve arm swing and as such optimize post-stroke gait rehabilitation.

Research questions:

  1. How can muscle synergies explain arm swing alterations in independent walkers after stroke?
  2. How do stroke-induced changes in cortical activity relate to arm swing deviations in persons after stroke?
  3. Are changes in primary motor control of the upper limb during walking related to normalization of brain activity in independent walkers after stroke?
03

Conditions studied

  • Healthy
  • Stroke

Browse trials for

Keywords

  • EMG
  • EEG
  • Gait
  • Arm swing
  • Kinematics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Stroke

Inclusion Criteria:

  • First-ever and cerebral stroke
  • Able to walk at least 10 minutes (FAC ≥ 3)
  • Presence of upper limb paresis (NIHSS item 5a/b > 0)

Exclusion Criteria:

  • Other neurological disorders

Healthy controls

Inclusion criteria:

  • Older than 18 years
  • Able to walk at least 10 minutes

Exlusion criteria:

  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Stroke

    Persons with a unilateral first ever stroke

    Other: Walking on a treadmill

  • Active comparator
    Control

    Age and gender matched healthy controls

    Other: Walking on a treadmill

Interventions

  • OtherWalking on a treadmill

    Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.

06

What researchers measure

Primary outcomes

  1. Number of muscle synergies

    The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors compared to healthy controls. Following muscles will be examined: * tibialis anterior, * gastrocnemius lateralis * soleus * vastus medialis * vastus lateralis * rectus femoris * biceps femoris * gluteus medius * erector spinae * latissimus dorsi * anterior deltoid * posterior deltoid * biceps brachii * triceps brachii

    Time frame: Single point of assessment at inclusion

  2. Number of muscle synergies

    The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors after a follow-up period of three months. Following muscles will be examined: * tibialis anterior, * gastrocnemius lateralis * soleus * vastus medialis * vastus lateralis * rectus femoris * biceps femoris * gluteus medius * erector spinae * latissimus dorsi * anterior deltoid * posterior deltoid * biceps brachii * triceps brachii

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

  3. Weight of muscle synergies

    The number or distribution of muscle weightings within a synergy during walking in stroke survivors compared to healthy controls. The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles: * tibialis anterior, * gastrocnemius lateralis * soleus * vastus medialis * vastus lateralis * rectus femoris * biceps femoris * gluteus medius * erector spinae * latissimus dorsi * anterior deltoid * posterior deltoid * biceps brachii * triceps brachii

    Time frame: Single point of assessment at inclusion

  4. Weight of muscle synergies

    The number or distribution of muscle weightings within a synergy during walking in stroke survivors after a follow-up period of three months. The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles: * tibialis anterior, * gastrocnemius lateralis * soleus * vastus medialis * vastus lateralis * rectus femoris * biceps femoris * gluteus medius * erector spinae * latissimus dorsi * anterior deltoid * posterior deltoid * biceps brachii * triceps brachii

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

  5. Brain symmetry index (BSI)

    The amount of cortical lateralization during walking in stroke survivors compared to healthy controls. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1.

    Time frame: Single point of assessment at inclusion

  6. Brain symmetry index (BSI)

    The amount of cortical lateralization during walking in stroke survivors after a follow-up period of three months. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1.

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

Secondary outcomes

  1. Upper limb kinematics

    Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°)

    Time frame: Single point of assessment at inclusion

  2. Upper limb kinematics

    Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°)

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

  3. Cortico-synergy coherence

    The amount of coherence (i.e. phase locking) between the muscle synergies and cortical activity during walking in stroke survivors compared to healthy controls. Higher values (0-1) indicate a better linear association.

    Time frame: Single point of assessment at inclusion

  4. Cortico-synergy coherence

    The amount of coherence (i.e phase locking) between the muscle synergies and cortical activity during walking in stroke survivors after a follow-up period of three months. Higher values (0-1) indicate a better linear association.

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

Other outcomes

  1. National Institutes of Health Stroke Scale (NIHSS)

    Quantifies the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42.

    Time frame: Single point of assessment at inclusion (only for stroke survivors)

  2. National Institutes of Health Stroke Scale (NIHSS)

    Quantifies the general impairment caused by a stroke after a follow-up period of three months. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42.

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

  3. Fugl-Meyer assesment - Upper limbs

    Assesses specifc motor impairments of the upper limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively.

    Time frame: Single point of assessment at inclusion (only for stroke survivors)

  4. Fugl-Meyer assesment - Upper limbs

    Assesses specifc motor impairments of the upper limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively.

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

  5. Tardieu scale

    Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2).

    Time frame: Single point of assessment at inclusion (only for stroke survivors)

  6. Tardieu scale

    Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2).

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

  7. 10 Meter Walking Test

    Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds).

    Time frame: Single point of assessment at inclusion (only for stroke survivors)

  8. 10 Meter Walking Test

    Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds).

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

  9. Fugl-Meyer assesment - Lower limbs

    Assesses specifc motor impairments of the lower limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively.

    Time frame: Single point of assessment at inclusion (only for stroke survivors)

  10. Fugl-Meyer assesment - Lower limbs

    Assesses specifc motor impairments of the lower limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively.

    Time frame: Single point of assessment 3 months after inclusion (only for stroke survivors)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 29 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Jul 9, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Sep 30, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06442579
Collaborators
University Ghent, VU University of Amsterdam, Vrije Universiteit Brussel
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jul 9, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Arne Defour, Msc.
Contact
Arne.Defour@UGent.be
09 332 12 43
Anke Van Bladel, PhD
Contact
Anke.VanBladel@UGent.be
09 332 12 43
Anke Van Bladel, PhD
principal investigator · Ghent University and Ghent University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion